[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642943":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":51,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Hospital de Santa Cruz, Portugal","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Cardiogenic Shock Registry Cohort",null,"Adult patients admitted with a diagnosis of cardiogenic shock between January 2017 and the end of the prospective recruitment period. All patients receive contemporary, standard clinical management for cardiogenic shock as determined by the clinical team, with no experimental interventions. Clinical, laboratory, imaging, and advanced hemodynamic monitoring data are systematically collected from hospital records to evaluate clinical performance and outcomes over time.",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"João Presume, MD","CONTACT","+351 21 043 1000","3134","jppereira@ulslo.min-saude.pt",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Unidade Local de Saúde de Lisboa Ocidental","RECRUITING","Carnaxide","Lisbon District","2790-134","Portugal","PT",{"type":29,"coordinates":30},"Point",[31,32],-9.24671,38.72706,{"lat":32,"lon":31},[35,36,39,41,43,45,47,49],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":18},{"name":37,"role":15,"phone":16,"phoneExt":10,"email":38},"Catarina Brízido, MD","cbrizido@ulslo.min-saude.pt",{"name":14,"role":40,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":37,"role":42,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":44,"role":42,"phone":10,"phoneExt":10,"email":10},"Ana Rita Bello, MD",{"name":46,"role":42,"phone":10,"phoneExt":10,"email":10},"Christopher Strong, MD",{"name":48,"role":42,"phone":10,"phoneExt":10,"email":10},"Manuel Sousa Almeida, PhD",{"name":50,"role":42,"phone":10,"phoneExt":10,"email":10},"Jorge Ferreira, MD",{"type":40,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"João Presume","MD","100642943","cardiovascular-outcomes-registry-in-cardiogenic-shock-cor-shock-100642943",false,"NCT07597291","Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)","Cardiovascular Outcomes Registry in Cardiogenic SHOCK","COR-SHOCK","Inclusion Criteria:\n\n-Cardiogenic shock according to the following criteria:\n\nCardiac disorder resulting in hypotension, defined as at least one of the following:\n\n* Systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or\n* Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg\n\nAND\n\nEvidence of tissue hypoperfusion, defined by the presence of at least one of the following:\n\n* Serum lactate \\>2 mmol\u002FL\n* Acute kidney injury and\u002For oliguria\n* Acute hepatic injury\n* Cool or mottled extremities\n* Altered mental status\n\nAND\n\nClinical presentation judged to be primarily attributable to a cardiac etiology.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).\n* Refusal to participate in the study (applicable only to the prospective cohort).","ALL","18 Years",{"count":65,"type":66},800,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:\n\n* How have management strategies and clinical outcomes for cardiogenic shock evolved over time?\n* How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?\n\nResearchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.\n\nParticipants will:\n\n* Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced).\n* Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay.\n* Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.",[70,71,72],"Cardiogenic Shock Acute","Cardiogenic Shock","Cardiogenic Shock Post Myocardial Infarction",[71,74,75,76,77,78,79,80],"Shock, Cardiogenic","Hemodynamic Monitoring","Pulmonary Artery Catheterization","Swan-Ganz","Mechanical Circulatory Support","Prognosis","Myocardial Infarction","2026-06-09",{"date":83,"type":84},"2026-06-11","ACTUAL",{"date":86,"type":84},"2026-06-10",{"date":88,"type":66},"2036-12-31",{"name":5,"class":6},1]